Tempus ECG-AF vs Us2.v2
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tempus ECG-AF is designed for predicting the risk of developing atrial fibrillation within 12 months by analyzing 12-lead ECGs, focusing on patients aged 65 or older without pre-existing AF. In contrast, Us2.v2 automates the interpretation of echocardiograms to deliver comprehensive reports on existing cardiac conditions. While both are FDA-cleared AI tools in cardiology, they address different diagnostic needs and utilize distinct cardiac imaging modalities.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Tempus ECG-AF is designed to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months by analyzing 12-lead ECG recordings. Us2.v2 automates echocardiogram interpretation, providing a complete structured echo report with measurements, disease detection, and clinical findings.
Tempus ECG-AF analyzes 12-lead ECG recordings. Us2.v2 analyzes echocardiograms, and is compatible with any ultrasound manufacturer, including handheld POCUS.
Tempus ECG-AF is intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, to detect signs associated with new onset AF. Us2.v2 offers automated detection of conditions such as cardiac amyloidosis, aortic stenosis, heart failure, pulmonary hypertension, and valvular disease.
Tempus ECG-AF is a software solution integrated into healthcare facility systems and is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems. Us2.v2 offers both cloud and on-premise deployment options, is compatible with any ultrasound manufacturer, and integrates seamlessly with existing PACS, CVIS, or EMR systems supporting HL7 and DICOM SR.
Yes, Tempus ECG-AF has CMS reimbursement available with CPT codes 0764T and 0765T, mapping to APC 5734, with a Medicare rate of $128.90 effective January 1, 2025. Us2.v2's pricing is custom based on deployment options and features, requiring contact with sales for a formal quotation, and no specific reimbursement codes are mentioned.
Tempus ECG-AF supports earlier identification and follow-up for patients at increased risk of developing AF. Us2.v2 offers 100% AI automation, eliminating manual frame selection and annotation, which can reduce reporting time by up to 70% and increase daily scan throughput.